ARS Pharmaceuticals reports Q3 EPS (20c), consensus (15c)

Reports Q3 revenue $2.1M, consensus $560,000. Cash, cash equivalents and short-term investments were $204.6M as of September 30. On a pro-forma basis, the Company’s cash, cash equivalents and short-term investments balance was $349.6M, adjusted for the $145M upfront payment from ALK-Abello in conjunction with the November 2024 licensing agreement. ARS Pharmaceuticals (SPRY) expects its capital to be sufficient to fund its current operating plan for at least three years. “The Q3 marked a transformative period for ARS Pharma, driven by the FDA approval of neffy in the U.S. and the European Commission approval of EURneffy in the European Union,” stated Richard Lowenthal, President and CEO of ARS. “With strong demand among healthcare providers and patients for neffy as the first and only needle-free epinephrine treatment, robust patient support systems in place, and favorable early payer discussions ongoing, we feel very good about the early momentum in our U.S. launch. We’re also proud to have further expanded the reach of neffy outside the U.S. by partnering with ALK-Abello, a global leader in allergy product commercialization. Operationally, we stand very well positioned with a balance sheet that is further strengthened by the $145M upfront payment from ALK, positioning us to execute our U.S. commercial plans and business goals to enable patients around the world to have access to this vital epinephrine treatment.”